Less Frequent Sequence Mismatches in Variants of Concern (VOCs) of SARS-CoV-2 in the Real-Time RT-PCR Assays Developed by the National Institute of Infectious Diseases, Japan

Various variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) began emerging worldwide from the end of 2020 to the beginning of 2021. The variants GRY/VOC202012/01 (B1.1.7), GH/N501Y.V2 (B1.351), and GR/N501Y.V3 (P1) are characterized by N to Y amino acid substitution at position...

Full description

Saved in:
Bibliographic Details
Published inJapanese Journal of Infectious Diseases Vol. 75; no. 1; pp. 96 - 101
Main Authors Shirato, Kazuya, Matsuyama, Shutoku, Takeda, Makoto
Format Journal Article
LanguageEnglish
Published Japan National Institute of Infectious Diseases, Japanese Journal of Infectious Diseases Editorial Committee 31.01.2022
Japan Science and Technology Agency
Subjects
Online AccessGet full text

Cover

Loading…
Abstract Various variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) began emerging worldwide from the end of 2020 to the beginning of 2021. The variants GRY/VOC202012/01 (B1.1.7), GH/N501Y.V2 (B1.351), and GR/N501Y.V3 (P1) are characterized by N to Y amino acid substitution at position 501 in the S protein. The variant containing L to R substitution at position 452 in the S protein G/L452R.V3 (B1.617) was endemic to India. The heightened concern regarding these variants is related to their increased viral infectivity. Information about nucleotide mismatch(es) on the primer/probe sequence is important for maintaining good performance of real-time PCR assays. In this study, real-time RT-PCR assays developed by the National Institute of Infectious Diseases, Japan (NIID-N2 and NIID-S2 assays), were reviewed to analyze nucleotide mismatches of variants in primer/probe sequences. The frequency of mismatched sequences in three variants (GRY/VOC202012/01, GH/N501Y.V2, and GR/N501Y.V3) was lower than that in all SARS-CoV-2 sequences. The mismatch, that G to C substitution at nucleotide 8 in reverse primer of S2 set, elevated to about 16.3% in G/L452R.V3, however the substitution did not affect the analytical sensitivity of assay. Therefore, the study indicates that the NIID-N2 and NIID-S2 sets detect VOCs of SARS-CoV-2 with reliable efficiency.
AbstractList Various variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) began emerging worldwide from the end of 2020 to the beginning of 2021. The variants GRY/VOC202012/01 (B1.1.7), GH/N501Y.V2 (B1.351), and GR/N501Y.V3 (P1) are characterized by N to Y amino acid substitution at position 501 in the S protein. The variant containing L to R substitution at position 452 in the S protein G/L452R.V3 (B1.617) was endemic to India. The heightened concern regarding these variants is related to their increased viral infectivity. Information about nucleotide mismatch(es) on the primer/probe sequence is important for maintaining good performance of real-time PCR assays. In this study, real-time RT-PCR assays developed by the National Institute of Infectious Diseases, Japan (NIID-N2 and NIID-S2 assays), were reviewed to analyze nucleotide mismatches of variants in primer/probe sequences. The frequency of mismatched sequences in three variants (GRY/VOC202012/01, GH/N501Y.V2, and GR/N501Y.V3) was lower than that in all SARS-CoV-2 sequences. The mismatch, that G to C substitution at nucleotide 8 in reverse primer of S2 set, elevated to about 16.3% in G/L452R.V3, however the substitution did not affect the analytical sensitivity of assay. Therefore, the study indicates that the NIID-N2 and NIID-S2 sets detect VOCs of SARS-CoV-2 with reliable efficiency.
Various variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) began emerging worldwide from the end of 2020 to the beginning of 2021. The variants GRY/VOC202012/01 (B1.1.7), GH/N501Y.V2 (B1.351), and GR/N501Y.V3 (P1) are characterized by N to Y amino acid substitution at position 501 in the S protein. The variant containing L to R substitution at position 452 in the S protein G/L452R.V3 (B1.617) was endemic to India. The heightened concern regarding these variants is related to their increased viral infectivity. Information about nucleotide mismatch(es) on the primer/probe sequence is important for maintaining good performance of real-time PCR assays. In this study, real-time RT-PCR assays developed by the National Institute of Infectious Diseases, Japan (NIID-N2 and NIID-S2 assays), were reviewed to analyze nucleotide mismatches of variants in primer/probe sequences. The frequency of mismatched sequences in three variants (GRY/VOC202012/01, GH/N501Y.V2, and GR/N501Y.V3) was lower than that in all SARS-CoV-2 sequences. The mismatch, that G to C substitution at nucleotide 8 in reverse primer of S2 set, elevated to about 16.3% in G/L452R.V3, however the substitution did not affect the analytical sensitivity of assay. Therefore, the study indicates that the NIID-N2 and NIID-S2 sets detect VOCs of SARS-CoV-2 with reliable efficiency.Various variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) began emerging worldwide from the end of 2020 to the beginning of 2021. The variants GRY/VOC202012/01 (B1.1.7), GH/N501Y.V2 (B1.351), and GR/N501Y.V3 (P1) are characterized by N to Y amino acid substitution at position 501 in the S protein. The variant containing L to R substitution at position 452 in the S protein G/L452R.V3 (B1.617) was endemic to India. The heightened concern regarding these variants is related to their increased viral infectivity. Information about nucleotide mismatch(es) on the primer/probe sequence is important for maintaining good performance of real-time PCR assays. In this study, real-time RT-PCR assays developed by the National Institute of Infectious Diseases, Japan (NIID-N2 and NIID-S2 assays), were reviewed to analyze nucleotide mismatches of variants in primer/probe sequences. The frequency of mismatched sequences in three variants (GRY/VOC202012/01, GH/N501Y.V2, and GR/N501Y.V3) was lower than that in all SARS-CoV-2 sequences. The mismatch, that G to C substitution at nucleotide 8 in reverse primer of S2 set, elevated to about 16.3% in G/L452R.V3, however the substitution did not affect the analytical sensitivity of assay. Therefore, the study indicates that the NIID-N2 and NIID-S2 sets detect VOCs of SARS-CoV-2 with reliable efficiency.
ArticleNumber JJID.2021.213
Author Matsuyama, Shutoku
Takeda, Makoto
Shirato, Kazuya
Author_xml – sequence: 1
  fullname: Shirato, Kazuya
  organization: Department of Virology III, National Institute of Infectious Diseases, Murayama Branch, Japan
– sequence: 2
  fullname: Matsuyama, Shutoku
  organization: Department of Virology III, National Institute of Infectious Diseases, Murayama Branch, Japan
– sequence: 3
  fullname: Takeda, Makoto
  organization: Department of Virology III, National Institute of Infectious Diseases, Murayama Branch, Japan
BackLink https://www.ncbi.nlm.nih.gov/pubmed/34193667$$D View this record in MEDLINE/PubMed
BookMark eNqFkc-O0zAQxiO0iP0DT4CELHFZJFLs2HGSY5VloVVhUVt6tRxnQl0Sp2u7SH0pnhGnLZXYCxePNfP7xp75rqML0xuIotcEj7I8px_2_U8wo-l0cjdKcEJGCaHPoiuS5yxOcsovwp0yFnOK2WV07dwG4yRNCX4RXVJGCsp5dhX9noFz6N7C4w6MR4tDVIC-aNdJr9bgkDZoJa2WxjvUN6jsQ90adLt6KN27IbMYzxdx2a_iZGD9GtAcZBsvdRduy_hbOUdj5-TeoTv4BW2_hRpV-wP4VXrdG9miiXFe-52HoeHENKBCYRcU2oF04N6jqdxK8zJ63sjWwatTvIm-339clp_j2cOnSTmexYpz7OMGy4QnVcWzlEtVQUYzzCTUYUWQprzBTU0IhwoUCwnJMYSF1TUrKsKLBoDeRLfHvlvbh404LzrtFLStNBC-JZKUZSnNioIF9O0TdNPvbJgpUDxhPGdZQQP15kTtqg5qsbW6k3Yv_joRAHoElO2ds9CcEYLF4Lc4-C0Gv8XgtwjDBFXxRKW0P-zUW6nb_2gnR-3GefkDzu9J67Vq4aTJUkGG4x_tmVFraQUY-ge-dcwj
CitedBy_id crossref_primary_10_1016_j_jviromet_2023_114812
crossref_primary_10_7883_yoken_JJID_2022_556
crossref_primary_10_3390_pathogens11030302
crossref_primary_10_1038_s41467_022_33911_8
crossref_primary_10_1128_jvi_01853_24
crossref_primary_10_1128_spectrum_00986_24
Cites_doi 10.1093/cid/ciab411
10.1128/JCM.00921-21
10.1038/s41586-020-2008-3
10.2807/1560-7917.ES.2020.26.1.2002106
10.1126/science.abg3055
10.1038/s41586-021-03324-6
10.1038/s41586-021-03402-9
10.7883/yoken.JJID.2020.1079
10.7883/yoken.JJID.2020.061
10.1093/bib/bbx108
10.1101/2021.01.26.21250543
ContentType Journal Article
Copyright 2022 Authors
Copyright Japan Science and Technology Agency 2022
Copyright_xml – notice: 2022 Authors
– notice: Copyright Japan Science and Technology Agency 2022
DBID AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7QL
7T5
7T7
7TK
7U9
8FD
C1K
FR3
H94
M7N
P64
7X8
DOI 10.7883/yoken.JJID.2021.213
DatabaseName CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
Bacteriology Abstracts (Microbiology B)
Immunology Abstracts
Industrial and Applied Microbiology Abstracts (Microbiology A)
Neurosciences Abstracts
Virology and AIDS Abstracts
Technology Research Database
Environmental Sciences and Pollution Management
Engineering Research Database
AIDS and Cancer Research Abstracts
Algology Mycology and Protozoology Abstracts (Microbiology C)
Biotechnology and BioEngineering Abstracts
MEDLINE - Academic
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
Virology and AIDS Abstracts
Technology Research Database
Bacteriology Abstracts (Microbiology B)
Algology Mycology and Protozoology Abstracts (Microbiology C)
AIDS and Cancer Research Abstracts
Immunology Abstracts
Engineering Research Database
Industrial and Applied Microbiology Abstracts (Microbiology A)
Neurosciences Abstracts
Biotechnology and BioEngineering Abstracts
Environmental Sciences and Pollution Management
MEDLINE - Academic
DatabaseTitleList Virology and AIDS Abstracts
MEDLINE

MEDLINE - Academic
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1884-2836
EndPage 101
ExternalDocumentID 34193667
10_7883_yoken_JJID_2021_213
article_yoken_75_1_75_JJID_2021_213_article_char_en
Genre Journal Article
GeographicLocations Japan
GeographicLocations_xml – name: Japan
GroupedDBID ---
.55
29J
2WC
53G
5GY
ACPRK
ADBBV
AENEX
AFRAH
ALMA_UNASSIGNED_HOLDINGS
BAWUL
DIK
DU5
E3Z
EBS
EJD
F5P
FRP
GX1
JSF
JSH
KQ8
OK1
RJT
RNS
RZJ
TR2
W2D
X7M
XSB
AAYXX
CITATION
OVT
CGR
CUY
CVF
ECM
EIF
NPM
7QL
7T5
7T7
7TK
7U9
8FD
C1K
FR3
H94
M7N
P64
7X8
ID FETCH-LOGICAL-c660t-f0a262bb6756acbe73704aed213e556f0fd116ebec43e5a60e836dd49b169fee3
ISSN 1344-6304
1884-2836
IngestDate Thu Jul 10 18:48:37 EDT 2025
Mon Jun 30 11:56:39 EDT 2025
Thu Jan 02 22:55:51 EST 2025
Thu Apr 24 22:53:09 EDT 2025
Tue Jul 01 03:55:16 EDT 2025
Thu Aug 17 20:30:00 EDT 2023
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 1
Keywords real-time RT-PCR
variant of concern (VOC)
severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
coronavirus diseases 2019 (COVID-19)
Language English
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-c660t-f0a262bb6756acbe73704aed213e556f0fd116ebec43e5a60e836dd49b169fee3
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
OpenAccessLink https://www.jstage.jst.go.jp/article/yoken/75/1/75_JJID.2021.213/_article/-char/en
PMID 34193667
PQID 2624684793
PQPubID 2048383
PageCount 6
ParticipantIDs proquest_miscellaneous_2547537994
proquest_journals_2624684793
pubmed_primary_34193667
crossref_primary_10_7883_yoken_JJID_2021_213
crossref_citationtrail_10_7883_yoken_JJID_2021_213
jstage_primary_article_yoken_75_1_75_JJID_2021_213_article_char_en
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2022/01/31
PublicationDateYYYYMMDD 2022-01-31
PublicationDate_xml – month: 01
  year: 2022
  text: 2022/01/31
  day: 31
PublicationDecade 2020
PublicationPlace Japan
PublicationPlace_xml – name: Japan
– name: Tokyo
PublicationTitle Japanese Journal of Infectious Diseases
PublicationTitleAlternate Jpn J Infect Dis
PublicationYear 2022
Publisher National Institute of Infectious Diseases, Japanese Journal of Infectious Diseases Editorial Committee
Japan Science and Technology Agency
Publisher_xml – name: National Institute of Infectious Diseases, Japanese Journal of Infectious Diseases Editorial Committee
– name: Japan Science and Technology Agency
References 12. Tchesnokova V, Kulakesara H, Larson L, et al. Acquisition of the L452R mutation in the ACE2-binding interface of Spike protein triggers recent massive expansion of SARS-Cov-2 variants. J Clin Microbiol. 2021;59:e0092121.
14. Katoh K, Rozewicki J, Yamada KD. MAFFT online service: multiple sequence alignment, interactive sequence choice and visualization. Brief Bioinform. 2019;20:1160-1166.
4. Shirato K, Tomita Y, Katoh H, et al. Performance evaluation of real-time RT-PCR assays for detection of severe acute respiratory syndrome coronavirus-2 developed by the National Institute of Infectious Diseases, Japan. Jpn J Infect Dis. 2021;74:465-472.
3. Shirato K, Nao N, Katano H, et al. Development of genetic diagnostic methods for detection for novel coronavirus 2019(nCoV-2019) in Japan. Jpn J Infect Dis. 2020;73:304-307.
11. Latif AA, Mullen JL, Alkuzweny M, et al. India Mutation Report. Available at <https://outbreak.info/location-reports?loc=IND>. Accessed May 26, 2021.
5. Davies NG, Abbott S, Barnard RC, et al. Estimated transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in England. Science. 2021;372:eabg3055.
6. Tegally H, Wilkinson E, Giovanetti M, et al. Detection of a SARS-CoV-2 variant of concern in South Africa. Nature. 2021;592:438-443.
1. Wu F, Zhao S, Yu B, et al. A new coronavirus associated with human respiratory disease in China. Nature. 2020;579:265-269.
8. Leung K, Shum MH, Leung GM, et al. Early transmissibility assessment of the N501Y mutant strains of SARS-CoV-2 in the United Kingdom, October to November 2020. Euro Surveill. 2021;26:2002106.
10. Wang Z, Schmidt F, Weisblum Y, et al. mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants. Nature. 2021;592:616-622.
13. Yadav PD, Sapkal GN, Abraham P, et al. Neutralization of variant under investigation B.1.617 with sera of BBV152 vaccinees. Clin Infect Dis. 2021; ciab411. doi: 10.1093/cid/ciab411.
2. World Health Organization (WHO). WHO Coronavirus Disease (COVID-19) Dashboard. Available at <https://covid19.who.int/>. Accessed October 21, 2020.
9. Jangra S, Ye C, Rathnasinghe R, et al. The E484K mutation in the SARS-CoV-2 spike protein reduces but does not abolish neutralizing activity of human convalescent and post-vaccination sera. medRxiv. 2021. doi: https://doi.org/10.1101/2021.01.26.21250543. Preprint.
7. National Institute of Infectious Diseases, Japan. Brief report: New Variant Strain of SARS-CoV-2 Identified in Travelers from Brazil. Available at <https://www.niid.go.jp/niid/images/epi/corona/covid19-33-en-210112.pdf>. Accessed March 9, 2021.
11
12
13
14
1
2
3
4
5
6
7
8
9
10
References_xml – reference: 1. Wu F, Zhao S, Yu B, et al. A new coronavirus associated with human respiratory disease in China. Nature. 2020;579:265-269.
– reference: 3. Shirato K, Nao N, Katano H, et al. Development of genetic diagnostic methods for detection for novel coronavirus 2019(nCoV-2019) in Japan. Jpn J Infect Dis. 2020;73:304-307.
– reference: 6. Tegally H, Wilkinson E, Giovanetti M, et al. Detection of a SARS-CoV-2 variant of concern in South Africa. Nature. 2021;592:438-443.
– reference: 7. National Institute of Infectious Diseases, Japan. Brief report: New Variant Strain of SARS-CoV-2 Identified in Travelers from Brazil. Available at <https://www.niid.go.jp/niid/images/epi/corona/covid19-33-en-210112.pdf>. Accessed March 9, 2021.
– reference: 8. Leung K, Shum MH, Leung GM, et al. Early transmissibility assessment of the N501Y mutant strains of SARS-CoV-2 in the United Kingdom, October to November 2020. Euro Surveill. 2021;26:2002106.
– reference: 10. Wang Z, Schmidt F, Weisblum Y, et al. mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants. Nature. 2021;592:616-622.
– reference: 12. Tchesnokova V, Kulakesara H, Larson L, et al. Acquisition of the L452R mutation in the ACE2-binding interface of Spike protein triggers recent massive expansion of SARS-Cov-2 variants. J Clin Microbiol. 2021;59:e0092121.
– reference: 14. Katoh K, Rozewicki J, Yamada KD. MAFFT online service: multiple sequence alignment, interactive sequence choice and visualization. Brief Bioinform. 2019;20:1160-1166.
– reference: 9. Jangra S, Ye C, Rathnasinghe R, et al. The E484K mutation in the SARS-CoV-2 spike protein reduces but does not abolish neutralizing activity of human convalescent and post-vaccination sera. medRxiv. 2021. doi: https://doi.org/10.1101/2021.01.26.21250543. Preprint.
– reference: 2. World Health Organization (WHO). WHO Coronavirus Disease (COVID-19) Dashboard. Available at <https://covid19.who.int/>. Accessed October 21, 2020.
– reference: 5. Davies NG, Abbott S, Barnard RC, et al. Estimated transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in England. Science. 2021;372:eabg3055.
– reference: 11. Latif AA, Mullen JL, Alkuzweny M, et al. India Mutation Report. Available at <https://outbreak.info/location-reports?loc=IND>. Accessed May 26, 2021.
– reference: 4. Shirato K, Tomita Y, Katoh H, et al. Performance evaluation of real-time RT-PCR assays for detection of severe acute respiratory syndrome coronavirus-2 developed by the National Institute of Infectious Diseases, Japan. Jpn J Infect Dis. 2021;74:465-472.
– reference: 13. Yadav PD, Sapkal GN, Abraham P, et al. Neutralization of variant under investigation B.1.617 with sera of BBV152 vaccinees. Clin Infect Dis. 2021; ciab411. doi: 10.1093/cid/ciab411.
– ident: 2
– ident: 13
  doi: 10.1093/cid/ciab411
– ident: 12
  doi: 10.1128/JCM.00921-21
– ident: 1
  doi: 10.1038/s41586-020-2008-3
– ident: 8
  doi: 10.2807/1560-7917.ES.2020.26.1.2002106
– ident: 11
– ident: 5
  doi: 10.1126/science.abg3055
– ident: 10
  doi: 10.1038/s41586-021-03324-6
– ident: 6
  doi: 10.1038/s41586-021-03402-9
– ident: 4
  doi: 10.7883/yoken.JJID.2020.1079
– ident: 7
– ident: 3
  doi: 10.7883/yoken.JJID.2020.061
– ident: 14
  doi: 10.1093/bib/bbx108
– ident: 9
  doi: 10.1101/2021.01.26.21250543
SSID ssj0025510
Score 2.3118782
Snippet Various variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) began emerging worldwide from the end of 2020 to the beginning of 2021. The...
SourceID proquest
pubmed
crossref
jstage
SourceType Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 96
SubjectTerms Amino acid substitution
Amino acids
Assaying
Communicable Diseases
coronavirus diseases 2019 (COVID-19)
Coronaviruses
COVID-19
Humans
Infectious diseases
Infectivity
Japan
Mutation
Nucleotides
Polymerase chain reaction
Protein G
Proteins
Real time
Real-Time Polymerase Chain Reaction
real-time RT-PCR
Respiratory diseases
Reverse Transcriptase Polymerase Chain Reaction
SARS-CoV-2
Severe acute respiratory syndrome coronavirus 2
severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
Substitutes
variant of concern (VOC)
Viral diseases
Title Less Frequent Sequence Mismatches in Variants of Concern (VOCs) of SARS-CoV-2 in the Real-Time RT-PCR Assays Developed by the National Institute of Infectious Diseases, Japan
URI https://www.jstage.jst.go.jp/article/yoken/75/1/75_JJID.2021.213/_article/-char/en
https://www.ncbi.nlm.nih.gov/pubmed/34193667
https://www.proquest.com/docview/2624684793
https://www.proquest.com/docview/2547537994
Volume 75
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
ispartofPNX Japanese Journal of Infectious Diseases, 2022/01/31, Vol.75(1), pp.96-101
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1fb9MwELeqgRAviP8UBjISD6AtpUkcJ3kchWmrKKC2q_oWOYnDRiFBTfrQfSg-Fp-Duzh2m2lMjJeodZxTkvv5fOf87kzIqyQDk5cFiSW9MLSYsGHMSS4sEfDEDTIvDusSG6NP_OiEDefevNP5vcVaWlVxLzm_NK_kf7QKbaBXzJK9hmaNUGiA36BfOIKG4fhPOv6IZupwWbOhKxj2ihW9NzorwQ_FnbBwNWMG0bAmuwwwSXGJ-g5mnwclLglg0srBeGINipnlaNbjGNxHC7ND9sZT68tgjFoU61JTjBqvFemRei2xRTo4bhheqxKre-IHIIUWmJjzljeMDbKU7foV5trm45Hx-ienNSlAkUDOV2szo4xEVcLfH7UjPDldVcVitVmSWMhUqLSkRVEV28scDvJF9PygLLPLmMVdtVdxT6q2IGAW-Ed825yrjVhasFW2OeRbs7ytllAuTiB-EGAhi3WxkHlvODx-34N7sXuOypdtl-u-MI0aciOEVSgmqoVEKCRCIZGDmyvfcCCcqZPS54aKBFGdqpqhH1FVx0Ihby-5k5YHdfMbBBFf5d_jo9pPmt4ld5oAhx4otN4jHZnfJ7dGDYXjAfmFoKUatFSDlm5AS89yqkFLi4w2oKWvEbJvsGUDWOwLOKQGsFQBlirAUgNYGq_rjhqw1AAWBW4ASzVg92mNzofk5PDDdHBkNZuGWAnn_crK-sLhThxDIMxFEkvf9ftMyBRenPQ8nvWz1LY5mi4GDYL3JeAnTVkY2zzMpHQfkZ28yOUTQmNPpAw3zJMZYzzloR1KAXJ9OxNe4vld4mhFRElTUR83dvkeXQGBLtk3F_1UBWWu7v5Oadh0bqxN09n3IhsPrYtMH8zcBEPZJbsaHVEzoMsI3hLjAS6sd8lLcxomF_xiCIMfXnnkeMz3XD8MWZc8Vqgy94GFIF3O_afXe6Bn5PZmeO-SnWq5ks_Br6_iF_Wg-APA1_tz
linkProvider Geneva Foundation for Medical Education and Research
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Less+Frequent+Sequence+Mismatches+in+Variants+of+Concern+%28VOCs%29+of+SARS-CoV-2+in+the+Real-Time+RT-PCR+Assays+Developed+by+the+National+Institute+of+Infectious+Diseases%2C+Japan&rft.jtitle=Japanese+journal+of+infectious+diseases&rft.au=Shirato%2C+Kazuya&rft.au=Matsuyama%2C+Shutoku&rft.au=Takeda%2C+Makoto&rft.date=2022-01-31&rft.issn=1344-6304&rft.eissn=1884-2836&rft.volume=75&rft.issue=1&rft.spage=96&rft.epage=101&rft_id=info:doi/10.7883%2Fyoken.JJID.2021.213&rft.externalDBID=n%2Fa&rft.externalDocID=10_7883_yoken_JJID_2021_213
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1344-6304&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1344-6304&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1344-6304&client=summon